Article Text

Download PDFPDF

AB0482 PHARMACOLOGICAL TREATMENT OF ENTHESITIS - A SYSTEMATIC REVIEW ON THE EFFICACY OF THE AVAILABLE OPTIONS
  1. R. Pinheiro Torres1,2,
  2. S. Rodrigues-Manica1,2,
  3. F. Pimentel Dos Santos1,2,3
  1. 1Hospital Egas Moniz, Rheumatology, Lisboa, Portugal
  2. 2CEDOC, Rheumatology, Lisboa, Portugal
  3. 3Nova Medical School, Rheumatology, Lisboa, Portugal

Abstract

Background: Enthesitis is a recognized as a hallmark of spondyloarthrtis (SpA), including psoriatic arthritis (PsA). However, it is an underestimated disease domain in both in clinical trials and clinical practice (1).

Objectives: This systematic literature review (SLR) assessed the efficacy of the available pharmacological options for enthesitis.

Methods: A SLR was conducted following the PRISMA reporting guidelines. Studies were sourced from PubMed and Embase databases, using the MeSH terms: enthesitis, entheses, treatment, spondylarthritis, ankylosing spondylitis and psoriatic arthritis. The search was limited to articles in English published between January 2000 and July 2020. Two independent reviewers screened the titles and abstracts.

Results: A total of 65 articles matched the research criteria. The included populations, the time to assessment of the primary endpoint and the chosen outcome for assessment of enthesitis was heterogeneous across studies. There were no studies assessing the effect of non-steroidal anti-inflammatory drugs, glucocorticoids, or csDMARDs. In PsA, all TNFis showed superiority in monotherapy against placebo (PBO). However, when combined with methotrexate (MTX), only some TNFi showed superiority against MTX monotherapy. In SpA, there was conflicting evidence regarding the efficacy of TNFi in enthesitis. Regarding IL23i in PsA, Ustekinumab was superior to PBO, and to TNFis. Guselkumab was superior to PBO when given every 4 weeks. Regarding IL7i, Secukinumab (SEC) was superior to PBO, only for some dosing schemes. Ixekizumab (IXE) was superior to PBO for the treatment of enthesitis only in TNF-naïve patients. Studies comparing SEC and IXE to ADA, showed no difference. There was no reported data on IL17i for enthesitis in SpA. In PsA, Tofacitinib was superior to PBO in naïve patients, and Tofacitinib 10mg was superior to PBO in bioexperienced patients. Apresmilast 30mg showed superiority to PBO for enthesitis. All finding are summarized on Table 1.

Table 1.

Findings of the systematic literature review on treatment options for enthesitis

Conclusion: This SLR emphasizes the current heterogeneity in the assessment and report of enthesitis. There is still an unmet need for further studies to improve our understanding about enthesopathy.

References: [1]Schett G. et al. Enthesitis: from pathophysiology to treatment. Nat Rev Rheumatol. 2017;13(12):731-41.

Disclosure of Interests: Rita Pinheiro Torres: None declared., Santiago Rodrigues-Manica Speakers bureau: Novartis, Janssen and MSD, Fernando Pimentel dos Santos: None declared.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.